Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. - Wikidata - wikimedia - TriplyDB

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

http://www.wikidata.org/entity/Q33203486

about

Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.The immune microenvironment of myeloma Ensemble learning for prediction of the bioactivity capacity of herbal medicines from chromatographic fingerprints.Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Immunotherapy in multiple myeloma--possibility or probability?Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Immunodeficiency and immunotherapy in multiple myeloma.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Dendritic cell vaccines for the immunocompromised patient: prevention of influenza virus infection.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Immunologic microenvironment and personalized treatment in multiple myeloma.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.Prediction of Radix Astragali Immunomodulatory Effect of CD80 Expression from Chromatograms by Quantitative Pattern-Activity Relationship.Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma.Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma.Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.

P2860

Q34257926-ECC66EB9-C8C5-4F05-BCE9-9E27DC50452F Q35603152-552ADDB2-4384-425E-9573-F8BD23488722 Q35761716-71CABD0D-4A66-46D0-A30A-DE7A5AA2B997 Q36038899-1F10ED32-BEAE-4BB1-B06E-0540C71F0990 Q36150417-44B82175-C1E5-44EB-B26E-6453E92485E5 Q36206601-69FD3E54-8844-4A76-8891-F2DDADFDA197 Q36498366-DC4E75A3-196C-473F-9610-2F6A0745C0C8 Q36689152-4ACA96BF-EC2C-4EC5-9956-093DD11CC241 Q36904977-2DEB9112-77B7-4526-BC07-88E6B31ED424 Q37035836-DD507F58-6610-43F8-8E7A-8FDFE84FFBFF Q37771941-9DDC1070-88FB-4208-B9E3-A6B86B5D269B Q38008379-7D8740F0-345D-41E7-9C30-7E6EC3F6C194 Q38108390-D6BDEEAB-70B9-4F01-ADD6-2DD85F423BD5 Q38219408-983ED2AA-ED0C-4A30-80E4-99C72D500683 Q38310281-5EBC6528-80C6-4239-B0D4-05F1F7908D0A Q38710878-D2CAFF48-8B8D-458F-9EF1-41F020B05EDA Q39758292-EAB76EFB-0A9D-4C04-8553-B5650F179F05 Q40342424-6B26294B-7574-4A32-898C-55DCC6C7B360 Q42417753-7F2F0D4D-D63F-44A1-8534-70B433899F88 Q46216910-8EC663FE-31E0-410D-AFDE-5AD10982F7B3

P2860

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

http://www.wikidata.org/entity/Q33203486

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Either interleukin-12 or inter ...... beta in patients with myeloma.

@ast

Either interleukin-12 or inter ...... beta in patients with myeloma.

@en

type

label

Either interleukin-12 or inter ...... beta in patients with myeloma.

@ast

Either interleukin-12 or inter ...... beta in patients with myeloma.

@en

prefLabel

Either interleukin-12 or inter ...... beta in patients with myeloma.

@ast

Either interleukin-12 or inter ...... beta in patients with myeloma.

@en

P1433

Q33203486-3DA41728-96B7-4088-9708-6CEFFD57F176

P1476

Q33203486-884D8C7F-1D54-475D-A61A-2342414CF72D

P2093

Q33203486-06E91118-BCAA-412A-AC9A-78D009E70184

Q33203486-2D8E1E42-AB80-4DD1-A810-ABB58214A062

Q33203486-5073AECF-9171-4A5C-AA1B-3AD9AED9D6A5

Q33203486-6AB0AD95-0835-4CD1-897E-193A25E46B9F

Q33203486-728B552F-A072-4601-BBAA-14494BD02682

Q33203486-8CE5BA3A-5A80-49BB-860D-1489993A905F

Q33203486-9FB370A7-7AF5-4744-9585-1CAC3F33152F

Q33203486-BC4B2761-4EC8-48C5-812E-BAD62F7251AC

P2860

Q33203486-14F22D85-98BF-45CD-87FB-F73B417D0B0C

Q33203486-51BF4A1E-7416-4ACB-99A9-81309E86B8FB

Q33203486-54D5E228-6631-4C9A-A52B-7064202E7594

Q33203486-65CBAD43-4E1C-41B9-BA5F-A2CE816BAD2C

Q33203486-67A821B8-2857-49B5-81D1-E1E5FCD56179

Q33203486-68947A48-8735-4860-AB22-DC7740BF7144

Q33203486-6E1F76B5-F9A2-4B17-AC61-88045E7EC189

Q33203486-78A184DA-1B93-4B11-8666-C2BFFCA5D7A1

Q33203486-9CA753FA-F520-449B-925F-DDCD5D6F3597

Q33203486-AEDC5544-D93E-4FCD-B882-8BF9E4081D85

P304

Q33203486-3EA083D3-CD9F-4540-B40C-24D19B2BE6C3

P31

Q33203486-BBF64921-3B2D-44A5-8C20-04E45A00CCEC

P356

Q33203486-94B96862-1DB0-4A52-A61F-A8AA5D40C802

P407

Q33203486-9D7F86B5-97A9-4118-84AE-9104F80CFDC4

P433

Q33203486-21C9C2A0-B925-43CE-97E7-FB30810263AC

P478

Q33203486-514FE694-E1BD-41B0-9C53-655D93E24A9E

P577

Q33203486-92160F26-632C-49CE-BF5D-6E5BF357B7D8

P5875

Q33203486-1A5362F9-60D8-4ACF-AC3A-22870FFBF74C

P698

Q33203486-86E9B0BE-2B1F-46F3-B0B9-9E8356549938

P356

J.1365-2141.2004.04984.X

P1433

British Journal of Haematology

P1476

Either interleukin-12 or inter ...... beta in patients with myeloma.

@en

P2093

Allan Murray

http://www.w3.org/2001/XMLSchema#string

Belinda Pope

http://www.w3.org/2001/XMLSchema#string

Daniel M Sze

http://www.w3.org/2001/XMLSchema#string

Derek Hart

http://www.w3.org/2001/XMLSchema#string

Doug Joshua

http://www.w3.org/2001/XMLSchema#string

John Gibson

http://www.w3.org/2001/XMLSchema#string

P Joy Ho

http://www.w3.org/2001/XMLSchema#string

Ross Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.

Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity.

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.

Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors.

Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments

4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12.

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.

CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination.

P304

743-748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2004.04984.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8525800

http://www.w3.org/2001/XMLSchema#string

P698

15180863

http://www.w3.org/2001/XMLSchema#string